GC Wellbeing Licenses Next-Gen Fat-Dissolving Injection for Korean Market

GC Wellbeing secures rights to next-gen fat-dissolving injection

GC Wellbeing said Monday it has signed a license-in agreement with Israeli biotech company Raziel Therapeutics to commercialize its next-generation localized fat-dissolving injectable treatment in Korea. Under the agreement, GC Wellbeing obtained exclusive rights to develop and market the candidate in Korea. The drug is currently being prepared for a Phase 3 clinical trial in the United States after completing discussions with the US Food and Drug Administration on the trial design The deal is e

By The Korea Herald